Recombinant Human Kallikrein 5 Protein, CF Best Seller
R&D Systems, part of Bio-Techne | Catalog # 1108-SE
Key Product Details
Source
NS0
Accession #
Structure / Form
Mature form
Conjugate
Unconjugated
Applications
Enzyme Activity
Product Specifications
Source
Mouse myeloma cell line, NS0-derived human Kallikrein 5 protein
Ile67-Ser293, with a C-terminal 10-His tag
Ile67-Ser293, with a C-terminal 10-His tag
Purity
>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
Endotoxin Level
<1.0 EU per 1 μg of the protein by the LAL method.
N-terminal Sequence Analysis
Ile67
Predicted Molecular Mass
27 kDa
SDS-PAGE
37-42 kDa, reducing conditions
Activity
Measured by its ability to cleave the fluorogenic peptide substrate Boc-VPR-AMC (Catalog # ES011).
The specific activity is >200 pmol/min/µg, as measured under the described conditions.
The specific activity is >200 pmol/min/µg, as measured under the described conditions.
Reviewed Applications
Read 1 review rated 4 using 1108-SE in the following applications:
Scientific Data Images for Recombinant Human Kallikrein 5 Protein, CF
Recombinant Human Kallikrein 5 Protein Enzyme Activity
Recombinant Human Kallikrein 5 (Catalog # 1108-SE) is measured by its ability to cleave the fluorogenic peptide substrate Boc-VPR-AMC (Catalog # ES011).Formulation, Preparation and Storage
1108-SE
| Formulation | Supplied as a 0.2 μm filtered solution in MES, NaCl and Glycerol. |
| Shipping | The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Background: Kallikrein 5
Human tissue Kallikrein 5 (hK5, also known as stratum corneum tryptic enzyme) is a serine protease of the human tissue Kallikrein gene family (2). The deduced amino acid sequence of human KLK5 consists of a signal peptide (Met1 to Gly22), a pro region (Val23 to Arg66) and a mature/active enzyme (Ile67 to Ser293). KLK5 is expressed mainly in skin, breast, brain and testis and to a lesser extent in many other tissues (3). KLK5 overexpression is an indicator of poor prognosis in ovarian cancer (4). hK5 is a candidate physiological activator of hK7 in the stratum corneum (5). Indeed, rhK5 can be used to activate rhK7 (R&D Systems, Catalog # 2624‑SE) by incubating rhK5 with recombinant human (rh) K7 (both at 0.1 mg/mL) in 25 mM MES, 0.15 M NaCl, pH 5.5, at 37 °C overnight.
rhK5 enzymatic activity can be inhibited by rhSerpinA1, A5, F2, and G1 (R&D Systems, Catalog # 1268‑PI, 1266‑PI, 1470-PI, 2488‑PI).
References
- Brattsand, M. and T. Egelrud (1999) J. Biol. Chem. 274:30033.
- Yousef, G.M. et al. (1999) Anticancer Res. 19:2843.
- Yousef, G.M. and E.P. Diamandis (2001) Endocrine Rev. 22:184.
- Yousef, G.M. and E.P. Diamandis (1999) J. Biol. Chem. 274:37511.
- Kim, H. et al. (2001) Br. J. Cancer 84:643.
Alternate Names
KLK-L2, KLK5, SCTE
Gene Symbol
KLK5
UniProt
Additional Kallikrein 5 Products
Product Documents for Recombinant Human Kallikrein 5 Protein, CF
Product Specific Notices for Recombinant Human Kallikrein 5 Protein, CF
For research use only
Loading...
Loading...
Loading...